TG Therapeutics (TGTX) Q4 2025 earnings review
BRIUMVI Blockbuster Trajectory Continues, Justifying Massive Commercial Investments
TG Therapeutics delivered a flawless quarter of commercial execution. BRIUMVI U.S. revenues reached $182.7 million in Q4, representing 76% YoY growth and driving the company to a massive $594 million full-year tally. The company's strategy of aggressive Direct-to-Consumer (DTC) marketing, highlighted by a new Super Bowl campaign with Christina Applegate, is paying off. Operating income surged 69% YoY to $50.5 million, though net income was optically flat due to a higher tax provision. With bold 2026 U.S. revenue guidance of $825-$850 million and the authorization of a second $100 million share buyback, management is projecting extreme confidence in its standalone MS franchise.
🐂 Bull Case
BRIUMVI continues to devour market share in the anti-CD20 segment. The 20% sequential revenue growth in Q4 proves that persistence rates and new patient starts are overcoming competitive pressures.
The ENHANCE trial (consolidated IV dosing) reads out mid-2026, and the highly anticipated subcutaneous formulation reads out by late 2026/early 2027. Success here would effectively double the total addressable market.
🐻 Bear Case
Management is guiding for ~$450 million in total cash OpEx for 2026 (including $100M for manufacturing start-up costs). This aggressive spending limits free cash flow generation in the near term.
Q1 2026 guidance of $185-$190 million implies sequential growth will decelerate sharply from 20% in Q4 to just ~2.6% in Q1, highlighting potential seasonality or market saturation headwinds.
⚖️ Verdict: 🟢
Bullish. The commercial execution is pristine. While operating expenses are ramping up significantly to fund manufacturing and DTC campaigns, the top-line growth and lifecycle management programs (Subcu and ENHANCE) easily justify the investment.
Key Themes
Commercial Execution: Mainstream Awareness Strategy
Management is turning to aggressive, mainstream DTC channels to drive growth, a notable shift for a commercial-stage biotech. The launch of the 'Next In MS' platform and a Super Bowl LX commercial featuring Christina Applegate represent a massive investment in brand awareness designed to pull demand directly from patients rather than relying solely on physician push.
Lifecycle Expansion: ENHANCE and Subcutaneous BRIUMVI
TG's moat relies on improving the patient experience to fight off Zunovo and Ocrevus. The pivotal ENHANCE trial, testing a consolidated Day 1 and Day 15 dosing regimen into a single 600 mg IV dose, is fully enrolled with data expected mid-2026. Simultaneously, the Phase 3 subcutaneous program is 75% enrolled (data late 2026/early 2027), which management believes can unlock the ~40% of the market that prefers self-administration.
Heavy Manufacturing and Supply Chain Capital Requirements
TG is incurring heavy upfront costs to secure its future supply chain. The 2026 guidance includes a specific ~$100 million carve-out for subcutaneous BRIUMVI manufacturing and secondary manufacturer start-up costs. This represents a significant capital drag that offsets top-line leverage, driving total cash OpEx significantly higher.
Aggressive Shareholder Returns
TG is utilizing its growing cash flow aggressively. The company completed its initial $100 million share repurchase program in Q3 (buying 3.5 million shares at ~$28.55) and immediately authorized a new $100 million program. This is highly unusual for a single-product biotech and signals management's supreme confidence in their balance sheet, which ended the year at $199.5 million.
Cost of Revenue Creep
Cost of revenue accelerated meaningfully in Q4 2025 to $38.1 million (vs $15.4M in Q4 2024), representing approximately 19.8% of total revenues compared to 14.2% a year ago. While total gross profit dollars remain spectacular, this 500+ bps margin compression warrants monitoring to ensure it is related to one-time partner dynamics or initial subcu manufacturing scale-up rather than structural pricing pressures.
Other KPIs
Accelerating. Up 69% from $29.9M in Q4 2024. This proves that despite the massive increase in SG&A ($62.7M) and R&D ($41.2M), BRIUMVI's top-line growth is generating significant operating leverage.
Stable YoY compared to $23.3M in Q4 2024. However, the optical flatness is driven almost entirely by taxes. In Q4 2025, TG recorded a $22.1M income tax expense, compared to just $2.1M in Q4 2024. The underlying business generated substantially more pre-tax profit ($45.1M vs $25.5M).
Accelerating. Revenue from ex-U.S. partner Neuraxpharm grew from $3.7M in 2024 to $12.8M in 2025, reflecting the rollout of BRIUMVI across the EU, UK, Switzerland, and Australia.
Guidance
Accelerating in absolute terms. The midpoint of $887.5M implies ~44% YoY growth over FY25's $616.3M. This assumes continued strong execution in the U.S. combined with accelerating partner sales in Europe and the Middle East.
Decelerating on a percentage basis, but stable in absolute dollars. The midpoint of $837.5M implies 41% YoY growth, down from 92% growth in 2025, but represents ~$243 million in newly generated U.S. revenue.
Decelerating sequentially. The $187.5M midpoint implies only 2.6% QoQ growth from Q4's $182.7M. This reflects typical Q1 pharmaceutical dynamics (deductible resets, gross-to-net pressures), but sets a conservative bar for the year.
Accelerating sharply. Total cash OpEx will reach approximately $450 million in 2026. The extra $100 million is entirely dedicated to subcu manufacturing and secondary manufacturer start-up, indicating management is willing to sacrifice short-term cash flow to secure supply and prep for a potential 2027/2028 subcu launch.
Key Questions
Gross-to-Net Pressures
With Q1 2026 U.S. revenue guidance implying low sequential growth vs Q4 2025, how much of this is driven by typical Q1 gross-to-net seasonality versus actual volume deceleration?
Cost of Goods Creep
Cost of revenues jumped significantly as a percentage of sales in Q4. Is this a temporary impact related to international partner sales mix, or are we seeing structural margin compression?
Secondary Manufacturer Start-Up
Guidance calls for $100M in manufacturing and secondary start-up costs. Is this secondary manufacturer entirely dedicated to the upcoming subcutaneous device, or is it mitigating geopolitical risks (e.g., tariffs) for the current IV supply chain?
DTC ROI Metrics
You are making a major investment in the Super Bowl and the 'Next In MS' platform. What leading indicators or conversion metrics are you tracking to ensure this large SG&A expenditure translates into tangible prescription volume?